These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
513 related items for PubMed ID: 12931221
1. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM, Falà F, Cocco L, Martelli AM. Leukemia; 2003 Nov; 17(11):2157-67. PubMed ID: 12931221 [Abstract] [Full Text] [Related]
3. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Nat Med; 2002 Oct 01; 8(10):1136-44. PubMed ID: 12244303 [Abstract] [Full Text] [Related]
4. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. Nat Med; 2002 Oct 01; 8(10):1153-60. PubMed ID: 12244302 [Abstract] [Full Text] [Related]
12. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Wang QM, Luo X, Studzinski GP. Cancer Res; 1997 Jul 15; 57(14):2851-5. PubMed ID: 9230188 [Abstract] [Full Text] [Related]